X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SCB-1019 is the company's bivalent RSV prefusion-stabilized F (PreF)-Trimer subunit vaccine candidate. It is being evaluated for the treatment of respiratory syncytial virus infections.
Lead Product(s): SCB-1019
Therapeutic Area: Infections and Infectious Diseases Product Name: SCB-1019
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2024
Details:
SCB-219M is an innovative TPO-RA mimetic bispecific Fc-fusion protein produced from CHO cells. It is under phase 1 clinical development for the treatment of cancer patients with chemotherapy-induced thrombocytopenia.
Lead Product(s): SCB-219M
Therapeutic Area: Hematology Product Name: SCB-219M
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 28, 2023
Details:
SCB-1019 is a vaccine drug candidate, which is currently being evaluated for the treatment of patients with respiratory syncytial virus (RSV) infections.
Lead Product(s): SCB-1019
Therapeutic Area: Infections and Infectious Diseases Product Name: SCB-1019
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2023
Details:
AdimFlu-S (QIS) is a quadrivalent split inactivated vaccine that can be used for the prevention of influenza. It contains hemagglutinin from four influenza virus strains (two A and two B).
Lead Product(s): Quadrivalent Seasonal Influenza Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: AdimFlu-S
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2023
Details:
Under the partnership, Clover will leverage Kyuan Trade’s extensive sales and distribution network to complement in-house capabilities and maximize access to its quadrivalent seasonal influenza vaccine, AdimFlu-S (QIS), across China.
Lead Product(s): Influenza A virus vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: AdimFlu-S
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Keyuan Xinhai
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 23, 2023
Details:
Under the terms of the agreement, Clover gains commercial rights to AdimFlu-S (quadrivalent influenza vaccine) in mainland China, Bangladesh, Brazil and the Philippines. AdimFlu-S is a quadrivalent split inactivated vaccine intended for use in the prevention of influenza.
Lead Product(s): Quadrivalent Influenza Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: AdimFlu-S
Highest Development Status: ApprovedProduct Type: Vaccine
Recipient: Adimmune
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 19, 2023
Details:
SCB-2019 antigen, a stabilized trimeric form of the S-protein based on the original strain of the SARS-CoV-2 virus, and combined it with Dynavax’s CpG 1018 advanced adjuvant and aluminum hydroxide (alum). Clover is developing it as a universal booster for COVID-19.
Lead Product(s): CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: SCB-2019
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2023
Details:
SCB-2019 antigen, a stabilized trimeric form of the S-protein based on the original strain of the SARS-CoV-2 virus, and combined it with Dynavax’s CpG 1018 advanced adjuvant and aluminum hydroxide (alum). Clover is developing it as a universal booster for COVID-19.
Lead Product(s): CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: SCB-2019
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 15, 2023
Details:
SCB-2019 (CpG 1018), a stabilized trimeric form of S-protein based on original strain of SARS-CoV-2 virus, demonstrated that household contact was 84% less likely to get SARS-CoV-2 infection when infected household member had received.
Lead Product(s): SCB-2019
Therapeutic Area: Infections and Infectious Diseases Product Name: SCB-2019
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: International Vaccine Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2022
Details:
SCB-2019 (CpG 1018) antigen, a stabilized trimeric form of the S-protein is based on the original strain of the SARS-CoV-2 virus. Clover created its COVID-19 vaccine candidate by combining SCB-2019 with Dynavax’s CpG 1018 advanced adjuvant and alum.
Lead Product(s): CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: SCB-2019
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
